CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets.
Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company’s operating results and an update on programs under development.
|
Schedule for the Operating Results Press Release, Conference Call / Audio Webcast |
|
|
Q2 Fiscal Year 2025 Results Press Release |
02/13/2025 at 7:30 a.m. ET |
|
Q2 Fiscal Year 2025 Conference Call-Live |
02/13/2025 at 11:00 a.m. ET |
|
US Toll Free Dial-In Number: |
1-888-506-0062 |
|
International Dial-In Number: |
1-973-528-0011 |
|
Participant Access Code: |
882092 |
|
Q2 Fiscal Year 2025 Conference Call-Replay |
02/13/2025-02/27/2025 |
|
US Toll Free Dial-In Number: |
1-877-481-4010 |
|
International Dial-In Number: |
1-919-882-2331 |
|
Participant Access Code: |
52016 |
The audio webcast and replay can be accessed by logging on to the “Investors-Webcasts” section of Palatin’s website at http://www.palatin.com or by clicking here.
About Palatin
Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at www.palatin.com and follow Palatin on Twitter at @PalatinTech.
SOURCE Palatin Technologies, Inc.
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of…
Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's…
Los Angeles, CA and Vancouver, BC, May 23, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc.…
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon…
INDIANAPOLIS, May 23, 2025 /PRNewswire/ -- This Memorial Day Weekend, the spotlight won't only be on…
IRVING, Texas, May 23, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="345px" width="400px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="12px" width="12px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="1000px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
